{"id":"aspirin-and-clopidogrel-prasugrel","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Bleeding (major and minor)"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"1-3","effect":"Gastrointestinal hemorrhage"},{"rate":"<0.1","effect":"Thrombotic thrombocytopenic purpura (TTP)"},{"rate":"<1","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet aggregation. Clopidogrel and prasugrel are P2Y12 receptor antagonists that block ADP-mediated platelet activation. The combination provides dual antiplatelet therapy (DAPT) to reduce stent thrombosis and recurrent ischemic events.","oneSentence":"Aspirin and clopidogrel/prasugrel are antiplatelet agents that inhibit platelet aggregation through different pathways to prevent thrombotic events.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:45.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)"},{"name":"Secondary prevention of stent thrombosis post-PCI"},{"name":"Stable coronary artery disease with stent placement"}]},"trialDetails":[{"nctId":"NCT05681702","phase":"PHASE4","title":"Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI","status":"RECRUITING","sponsor":"University of Florida","startDate":"2023-02-15","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT06588595","phase":"PHASE4","title":"The Switching Antiplatelet-9 (SWAP-9) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-11-01","conditions":"Coronary Arterial Disease (CAD)","enrollment":90},{"nctId":"NCT05531474","phase":"NA","title":"Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2020-11-02","conditions":"Cardiovascular Complication, Bariatric Surgery Candidate","enrollment":200},{"nctId":"NCT04014803","phase":"PHASE4","title":"Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2020-01-13","conditions":"Coronary Artery Disease","enrollment":3500},{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT06535568","phase":"NA","title":"Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","status":"RECRUITING","sponsor":"Fondazione Ricerca e Innovazione Cardiovascolare ETS","startDate":"2026-01-10","conditions":"Coronary Disease, Heart Diseases, Cardiovascular Diseases","enrollment":576},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT07032389","phase":"PHASE2","title":"A Polypill for Acute Coronary Syndrome","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-12-05","conditions":"Acute Coronary Syndrome","enrollment":1000},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT07164859","phase":"PHASE3","title":"Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI","status":"NOT_YET_RECRUITING","sponsor":"Vincent ROULE","startDate":"2025-10","conditions":"Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI), Antiplatelet Therapy","enrollment":1700},{"nctId":"NCT06665919","phase":"NA","title":"The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models","status":"COMPLETED","sponsor":"Vistamedi Ltd.","startDate":"2023-06-15","conditions":"Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis","enrollment":283},{"nctId":"NCT05514938","phase":"PHASE2","title":"Polypill in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-11-30","conditions":"Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease","enrollment":140},{"nctId":"NCT06763744","phase":"PHASE4","title":"Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-06-01","conditions":"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk","enrollment":3000},{"nctId":"NCT05952206","phase":"PHASE3","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","status":"RECRUITING","sponsor":"iVascular S.L.U.","startDate":"2023-10-13","conditions":"Coronary Artery Disease","enrollment":2312},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT03606642","phase":"PHASE2","title":"SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy","status":"TERMINATED","sponsor":"HonorHealth Research Institute","startDate":"2018-11-19","conditions":"Coronary Artery Disease, Atherosclerosis, Stent Placement","enrollment":50},{"nctId":"NCT05955365","phase":"PHASE4","title":"Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-12-18","conditions":"Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF), Oral Anticoagulation","enrollment":3010},{"nctId":"NCT06613191","phase":"PHASE4","title":"Colonoscopy and Antiplatelet Therapy Trial","status":"NOT_YET_RECRUITING","sponsor":"Ochsner Health System","startDate":"2024-10-01","conditions":"Coronary Arterial Disease (CAD), Peripheral Vascular Disease","enrollment":100},{"nctId":"NCT05418556","phase":"PHASE4","title":"Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-10-21","conditions":"Coronary Artery Disease","enrollment":3944},{"nctId":"NCT05117866","phase":"NA","title":"Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Meditrix Corp","startDate":"2020-09-15","conditions":"Chronic Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":307},{"nctId":"NCT02886962","phase":"PHASE4","title":"Oral Anticoagulation in Haemodialysis Patients","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2017-07-12","conditions":"Kidney Failure, Chronic","enrollment":50},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04609111","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2021-01-29","conditions":"Acute Coronary Syndrome","enrollment":6002},{"nctId":"NCT06400940","phase":"PHASE4","title":"Prospective, Post-registration, Interventional, Randomized, in Parallel Groups, Multicenter Eurasian Clinical Study of DERIVO®/DERIVO® Mini Aneurysm Embolization Device, Europe-Asia","status":"RECRUITING","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2023-08-17","conditions":"Intracranial Aneurysm","enrollment":640},{"nctId":"NCT05262803","phase":"PHASE4","title":"Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction","status":"RECRUITING","sponsor":"Rikke Sorensen","startDate":"2022-06-17","conditions":"Myocardial Infarction","enrollment":2808},{"nctId":"NCT05223335","phase":"PHASE4","title":"Clopidogrel Monotherapy in Patients With High Bleeding Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-03-29","conditions":"Bleeding Complications","enrollment":98},{"nctId":"NCT05773989","phase":"PHASE4","title":"Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy","status":"UNKNOWN","sponsor":"St. Antonius Hospital","startDate":"2024-01-23","conditions":"Coronary Artery Disease, Platelet Reactivity","enrollment":88},{"nctId":"NCT01106534","phase":"PHASE4","title":"XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2009-08","conditions":"Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia","enrollment":870},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT05821062","phase":"","title":"Antiplatelet Therapies in Patients With Depression and Coronary Disease","status":"UNKNOWN","sponsor":"Centro Cardiologico Monzino","startDate":"2022-04-14","conditions":"Coronary Artery Disease, Depression","enrollment":400},{"nctId":"NCT05122741","phase":"","title":"Modulation of Fibrosis-inducing Pathways in Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"University of Messina","startDate":"2021-12-01","conditions":"Myocardial Infarction, Myocardial Fibrosis, Myocardial Remodeling, Ventricular","enrollment":50},{"nctId":"NCT02601157","phase":"PHASE4","title":"Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-01-18","conditions":"Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction","enrollment":2173},{"nctId":"NCT05599152","phase":"","title":"Comparison of Myocardial Infarction Patients Who Were Prescribed a Novel Antiplatelet Agent or Clopidogrel","status":"UNKNOWN","sponsor":"Chan Joon Kim","startDate":"2020-05-21","conditions":"Myocardial Infarction","enrollment":3000},{"nctId":"NCT05359224","phase":"PHASE4","title":"Low Dose Prasugrel vs Clopidogrel for Stenting or Flow Diverter for Unruptured Aneurysm","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2022-06-13","conditions":"Intracranial Aneurysm","enrollment":406},{"nctId":"NCT03581409","phase":"PHASE4","title":"Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2018-10-24","conditions":"Aneurysm, Cerebral, Endovascular Procedures","enrollment":198},{"nctId":"NCT01452152","phase":"PHASE4","title":"Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2012-02","conditions":"Cardiovascular Diseases, Acute Coronary Syndrome","enrollment":9},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT01014624","phase":"PHASE4","title":"Prasugrel/Clopidogrel Maintenance Dose Washout Study","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2010-02","conditions":"Coronary Artery Disease","enrollment":56},{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":"Covid19","enrollment":1707},{"nctId":"NCT02866175","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2017-02-24","conditions":"Atrial Fibrillation","enrollment":1506},{"nctId":"NCT02247128","phase":"PHASE4","title":"Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2014-01","conditions":"Aortic Valve Disease, Myocardial Infarction, Stroke","enrollment":1016},{"nctId":"NCT04291287","phase":"","title":"Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)","status":"UNKNOWN","sponsor":"Scientific Institute San Raffaele","startDate":"2020-01-25","conditions":"Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding","enrollment":1500},{"nctId":"NCT02635230","phase":"","title":"What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.","status":"UNKNOWN","sponsor":"R&D Cardiologie","startDate":"2014-06","conditions":"Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes","enrollment":2200},{"nctId":"NCT03621020","phase":"","title":"Clinical Performance Evaluation of T-TAS 01 PL Chip","status":"COMPLETED","sponsor":"Hikari Dx, Inc.","startDate":"2018-09-01","conditions":"Platelet Dysfunction, Von Willebrand Diseases, Healthy","enrollment":307},{"nctId":"NCT02285751","phase":"PHASE2","title":"High \"on Treatment\" Platelet Reactivity in the Intensive Care Unit","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2012-11","conditions":"Critical Illness","enrollment":200},{"nctId":"NCT02030548","phase":"","title":"Bleeding in Patients Undergoing CABG (Coronary Artery Bypass Graft) During Dual Antiplatelet Therapy","status":"TERMINATED","sponsor":"Medical University of Graz","startDate":"2013-11","conditions":"Acute Coronary Syndrome","enrollment":144},{"nctId":"NCT00823212","phase":"PHASE3","title":"The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2009-01","conditions":"Coronary Artery Disease","enrollment":1530},{"nctId":"NCT01500434","phase":"PHASE3","title":"The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2009-02","conditions":"Coronary Artery Disease","enrollment":102},{"nctId":"NCT01510327","phase":"PHASE3","title":"PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2009-10","conditions":"Coronary Artery Disease","enrollment":22},{"nctId":"NCT02118870","phase":"PHASE4","title":"Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent","status":"COMPLETED","sponsor":"Diagram B.V.","startDate":"2014-06-10","conditions":"Acute Coronary Syndrome","enrollment":1500},{"nctId":"NCT01260584","phase":"PHASE4","title":"The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2010-11","conditions":"Coronary Artery Disease","enrollment":110},{"nctId":"NCT01589978","phase":"PHASE4","title":"PROMUS Element Plus US Post-Approval Study","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2012-05","conditions":"Coronary Artery Disease","enrollment":2681},{"nctId":"NCT03184805","phase":"NA","title":"STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation","status":"TERMINATED","sponsor":"Yonsei University","startDate":"2017-06-23","conditions":"Coronary Artery Disease","enrollment":140},{"nctId":"NCT03469856","phase":"NA","title":"Acetyl Salicylic Elimination Trial: The ASET Pilot Study","status":"UNKNOWN","sponsor":"Pedro A. Lemos","startDate":"2018-02-22","conditions":"Monotherapy After PCI","enrollment":200},{"nctId":"NCT01103440","phase":"PHASE2","title":"Aspirin Resistance and Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2007-04","conditions":"Stable Angina","enrollment":36},{"nctId":"NCT01433978","phase":"PHASE3","title":"A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2012-03-26","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":24},{"nctId":"NCT01438840","phase":"PHASE3","title":"Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-02-16","conditions":"Chronic Thrombocytopenia, Immune Thrombocytopenia","enrollment":49},{"nctId":"NCT02293395","phase":"PHASE2","title":"A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-04-20","conditions":"Acute Coronary Syndrome","enrollment":3037},{"nctId":"NCT01830543","phase":"PHASE3","title":"A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-05-10","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2124},{"nctId":"NCT00977938","phase":"PHASE4","title":"The Dual Antiplatelet Therapy Study (DAPT Study)","status":"COMPLETED","sponsor":"Baim Institute for Clinical Research","startDate":"2009-10","conditions":"Coronary Artery Disease","enrollment":25682},{"nctId":"NCT01069003","phase":"PHASE4","title":"EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events","status":"COMPLETED","sponsor":"Medtronic Vascular","startDate":"2010-04","conditions":"Coronary Artery Disease","enrollment":2272},{"nctId":"NCT02642419","phase":"PHASE4","title":"Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study","status":"UNKNOWN","sponsor":"Japan Cardiovascular Research Foundation","startDate":"2015-01","conditions":"Atrial Fibrillation","enrollment":2200},{"nctId":"NCT01582217","phase":"","title":"Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2012-03","conditions":"Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Aspirin","enrollment":318},{"nctId":"NCT02402491","phase":"PHASE4","title":"Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2013-01","conditions":"Percutaneous Coronary Intervention","enrollment":1000},{"nctId":"NCT02303717","phase":"NA","title":"Xience Versus Synergy in Left Main PCI","status":"UNKNOWN","sponsor":"NHS National Waiting Times Centre Board","startDate":"2014-12","conditions":"Coronary Artery Disease","enrollment":818},{"nctId":"NCT00954707","phase":"PHASE4","title":"CYPRESS - CYPHER for Evaluating Sustained Safety","status":"UNKNOWN","sponsor":"Cordis US Corp.","startDate":"2009-08","conditions":"Coronary Artery Disease","enrollment":2509},{"nctId":"NCT00699998","phase":"PHASE3","title":"A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-06","conditions":"Acute Coronary Syndrome","enrollment":9326},{"nctId":"NCT00827411","phase":"PHASE4","title":"Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-01","conditions":"Coronary Artery Disease, Acute Coronary Syndrome","enrollment":2500},{"nctId":"NCT01107912","phase":"PHASE1","title":"Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-03","conditions":"Coronary Artery Disease","enrollment":155},{"nctId":"NCT01107925","phase":"PHASE1","title":"Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-03","conditions":"Coronary Artery Disease","enrollment":72},{"nctId":"NCT01598337","phase":"PHASE3","title":"The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency","status":"UNKNOWN","sponsor":"Prince Sultan Cardiac Center, Adult Cardiology Department.","startDate":"2011-04","conditions":"Coronary Artery Disease","enrollment":200},{"nctId":"NCT01212302","phase":"NA","title":"Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)","status":"COMPLETED","sponsor":"Ruhr University of Bochum","startDate":"2008-10","conditions":"Coronary Artery Disease","enrollment":500},{"nctId":"NCT00385944","phase":"PHASE2","title":"The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-03","conditions":"Acute Coronary Syndrome","enrollment":56},{"nctId":"NCT00357968","phase":"PHASE2","title":"Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-08","conditions":"Coronary Artery Disease","enrollment":201}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":170,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Aspirin and clopidogrel / Prasugrel","genericName":"Aspirin and clopidogrel / Prasugrel","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aspirin and clopidogrel/prasugrel are antiplatelet agents that inhibit platelet aggregation through different pathways to prevent thrombotic events. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Secondary prevention of stent thrombosis post-PCI, Stable coronary artery disease with stent placement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}